Clinical trials: Thrombotic Microangiopathies
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Trial name
- NCT03518203
- Testing
- Eculizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Thrombotic Thrombocytopenic Purpura
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid…
- Trial name
- STAR (NCT00799773)
- Testing
- Rituximab, Plasma exchange, Corticosteroids
- Where
- 23 sites in United States
- Volunteers
- 3 people
- Sponsor
- Carelon Research
Primary Immune Thrombocytopenia
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.
- Trial name
- ADVANCE (NCT04188379)
- Testing
- efgartigimod
- Where
- 121 sites in United States, Austria and 16 more
- Volunteers
- 131 people
- Sponsor
- argenx
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant
A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).
The purpose of this study was to assess OS outcomes in pediatric (≥ 28 days of age at the time of HSCT-TMA diagnosis) and adult participants diagnosed with HSCT-TMA(referred to as TMA from hereon) within 52 weeks after HSCT and…
- Trial name
- ALX-TMA-502 (NCT07732361)
- Where
- 43 sites in United States, Belgium and 8 more
- Volunteers
- 307 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Immune Thrombocytopenic Purpura (ITP)
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic…
- Trial name
- NCT03866577
- Testing
- Biological: M254, Intravenous immunoglobulin (IVIg)
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Immune Thrombocytopenia
Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
The goal of this clinical trial is to demonstrate GL-2045 safety and efficacy proof of concept by demonstrating intravenous immunoglobulin (IVig)-like platelet responses in adult patients with Immune Thrombocytopenia (ITP).
- Trial name
- NCT07605845
- Testing
- GL-2045
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Gliknik Inc.
Immune Thrombocytopenia
ATRA for Management of Primary ITP
A multicenter, randomized, double-blind placebo-controlled study to report the efficacy and safety of all-trans etinoic acid compared to placebo for the treatment of adults with corticosteriod-resistant/relapsed primary immune…
- Trial name
- NCT07597395
- Testing
- all-trans retinoic acid (ATRA)
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Peking University People's Hospital
Idiopathic Thrombocytopenic Purpura
Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?
Idiopathic thrombocytopenic purpura (ITP) is a benign hematological disorder characterized by isolated thrombocytopenia. Development of antiplatelet autoantibodies is the main pathogenetic mechanism in patients with ITP.
- Trial name
- NCT04128358
- Testing
- Serological assay for blood born viral hepatitis, Quantitative microbiological test for HCV
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assiut University
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura
A Study of PN20 in Healthy Adult Volunteers
The main aim of this clinical trial is to assess the safety of PN20 in healthy volunteers aged 18 to 50 years. The main questions it aims to answer are: Is PN20 safe in adult? Researchers will compare PN20 to a placebo (a…
- Trial name
- NCT06523088
- Testing
- PN20
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Thrombotic Microangiopathies
Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Thrombotic microangiopathies (TMA) are defined as a triad combining mechanical hemolytic anemia, peripheral thrombocytopenia and ischemic organ damage.
- Trial name
- m-TMA (NCT06098378)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines.
- Trial name
- NCT01713855
- Testing
- Inactivated Trivalent Influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neufeld, Ellis J, MD, PhD
Thrombocytopenic Purpura
Lymphocyte Counts in Immune Thrombocytopenic Purpura
immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number (cooper N et al 2006) recent studies have demonstrated that the pathogenesis of ITP…
- Trial name
- NCT03244410
- Testing
- complete blood picture
- Volunteers
- 1 people
- Sponsor
- Assiut University
Thrombotic Microangiopathy
N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy
This multicenter, prospective, single-arm clinical trial aims to evaluate the efficacy and safety of N-acetylcysteine (NAC) for treating Transplantation-Associated Thrombotic Microangiopathy (TA-TMA), a severe complication of…
- Trial name
- NCT07279610
- Testing
- N-Acetylcysteine (NAC) Treatment
- Where
- China
- Volunteers
- 44 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Thrombotic Microangiopathies, Hematologic Diseases
A Safety and Efficacy Study of NAC in Patients With TA-TMA
HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement…
- Trial name
- NCT03252925
- Testing
- N-Acetylcysteine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Idiopathic Thrombocytopenic Purpura (ITP)
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
The primary purpose of this study is to evaluate the safety of multiple doses of Staphylococcal protein A (PRTX-100) in adult patients with Idiopathic Thrombocytopenia Purpura (ITP).
- Trial name
- NCT00571467
- Testing
- PRTX-100 (Staphylococcal protein A)
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 9 people
- Sponsor
- Protalex, Inc.
Immune Thrombocytopenia
Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. This study evaluates the safety and efficacy of universal STAR-T cells in patients with R/R CTD-associated Immune Thrombocytopenia (CTD-ITP).
- Trial name
- NCT07599280
- Testing
- Universal STAR-T Cell
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Jian Zhu
Immune Thrombocytopenia
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib. The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed…
- Trial name
- NCT07216079
- Testing
- rilzabrutinib
- Where
- 3 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Sanofi
aHUS, Atypical Hemolytic Uremic Syndrome
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
- Trial name
- NCT07308574
- Testing
- Ravulizumab
- Where
- 12 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Alexion Pharmaceuticals, Inc.